0 CHECKOUT

Oligodendroglioma - Pipeline Review, H2 2015

  • ID: 3455184
  • September 2015
  • 141 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Axelar AB
  • Cavion LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Oncolytics Biotech Inc.
  • Sanofi
  • MORE

Oligodendroglioma - Pipeline Review, H2 2015

Summary

The report ‘Oligodendroglioma - Pipeline Review, H2 2015’, provides an overview of the Oligodendroglioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Axelar AB
  • Cavion LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Oncolytics Biotech Inc.
  • Sanofi
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Oligodendroglioma Overview

Therapeutics Development

Pipeline Products for Oligodendroglioma - Overview

Pipeline Products for Oligodendroglioma - Comparative Analysis

Oligodendroglioma - Therapeutics under Development by Companies

Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes

Oligodendroglioma - Pipeline Products Glance

Clinical Stage Products

Oligodendroglioma - Products under Development by Companies

Oligodendroglioma - Products under Investigation by Universities/Institutes

Oligodendroglioma - Companies Involved in Therapeutics Development

Axelar AB

Boehringer Ingelheim GmbH

Cavion LLC

Celgene Corporation

Celldex Therapeutics, Inc.

e-Therapeutics Plc

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Millennium Pharmaceuticals, Inc.

Novartis AG

Oncolytics Biotech Inc.

Pfizer Inc.

Sanofi

Tocagen Inc.

Oligodendroglioma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

afatinib dimaleate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

alisertib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AXL-1717 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bevacizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CC-122 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CDX-1401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dendritic Cell Therapy for Gliomas - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Dendritic Cell Therapy for Oncology - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DNX-2401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ETS-2101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

galunisertib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mibefradil dihydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nilotinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

panobinostat - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pelareorep - Drug Profile

Product Description

Mechanism of Action

R&D Progress

plerixafor - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Glioma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

temsirolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vocimagene amiretrorepvec + flucytosine ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oligodendroglioma - Recent Pipeline Updates

Oligodendroglioma - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Oligodendroglioma, H2 2015

Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Oligodendroglioma - Pipeline by Axelar AB, H2 2015

Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H2 2015

Oligodendroglioma - Pipeline by Cavion LLC, H2 2015

Oligodendroglioma - Pipeline by Celgene Corporation, H2 2015

Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H2 2015

Oligodendroglioma - Pipeline by e-Therapeutics Plc, H2 2015

Oligodendroglioma - Pipeline by Eli Lilly and Company, H2 2015

Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015

Oligodendroglioma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015

Oligodendroglioma - Pipeline by Novartis AG, H2 2015

Oligodendroglioma - Pipeline by Oncolytics Biotech Inc., H2 2015

Oligodendroglioma - Pipeline by Pfizer Inc., H2 2015

Oligodendroglioma - Pipeline by Sanofi, H2 2015

Oligodendroglioma - Pipeline by Tocagen Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Oligodendroglioma Therapeutics - Recent Pipeline Updates, H2 2015

Oligodendroglioma - Dormant Projects, H2 2015

List of Figures

Number of Products under Development for Oligodendroglioma, H2 2015

Number of Products under Development for Oligodendroglioma - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Axelar AB
Boehringer Ingelheim GmbH
Cavion LLC
Celgene Corporation
Celldex Therapeutics, Inc.
e-Therapeutics Plc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Millennium Pharmaceuticals, Inc.
Novartis AG
Oncolytics Biotech Inc.
Pfizer Inc.
Sanofi
Tocagen Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Qiagen N.V.
  • Elekta AB
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb
  • Genentech, Inc.